Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 6,500 shares of common stock for approximately $4.97 per share.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. [SER], reported a transaction on October 20, 2025.
• The transaction involved the exercise of 6,500 stock options at an exercise price of $0.06 per share.
• Immediately following the exercise, 6,500 shares of common stock were sold at a weighted average price of $4.9672 per share.
• The sales occurred in multiple transactions with prices ranging from $4.88 to $5.02 per share.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Randall Moreadith beneficially owns 410,686 stock options.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, indicating a neutral impact on company sentiment. It reflects an officer realizing value from vested options.

Positives

• The Chief Scientific Officer realized a gain from exercising options at $0.06 and selling shares at an average of $4.9672.
• The transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new material non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the officer's direct equity stake.

Future Outlook

N/A. This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

N/A. This Form 4 filing reports an individual insider transaction and does not provide information relevant to broader industry trends or competitor analysis.

Related Party Transactions

• The reported transaction involves an officer of the company, Randall Moreadith, exercising options and selling shares, which is a related party transaction. No other related party dealings involving the company are disclosed in this filing.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though mitigated by the 10b5-1 plan and the relatively small volume of shares.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Keywords

Serina Therapeutics, SER, Randall Moreadith, Form 4, insider trading, stock options, equity sale, Chief Scientific Officer, 10b5-1 plan